<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> or cerebrovascular injury is the leading cause of disability and the third leading cause of <z:hpo ids='HP_0011420'>deaths</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>After the initial ischemic injury, sympathetic signals are transmitted to the spleen and a compromised blood-brain barrier, coupled with expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules by the vascular endothelial cells permits an influx of peripheral immune cells </plain></SENT>
<SENT sid="2" pm="."><plain>This influx of peripheral immune cells into the brain exacerbates the local brain <z:mp ids='MP_0001845'>inflammatory response</z:mp>, leading to enhanced <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="17431">Agmatine</z:chebi> is a <z:chebi fb="0" ids="32877">primary amine</z:chebi> formed by decarboxylation of <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> synthesized in the mammalian brain </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we determined the effect of <z:chebi fb="0" ids="17431">agmatine</z:chebi> on the immune response in the spleen after transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-three hours after transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, the white pulp area was reduced and the number of CD11b(+) macrophages and CD4(+)CD25(+) regulatory T cells (T reg cells) were increased in the spleens in the experimental group as a result of alteration of the immune response in the spleen, as regulated by inflammatory cytokines </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:chebi fb="0" ids="17431">agmatine</z:chebi> treatment group (100 mg/kg IP), the contraction of white pulp was diminished and the number of CD11b(+) macrophages and CD4(+)CD25(+)T reg cells were decreased </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-three hours after transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, the <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> area was significantly reduced (5.51±1.63% of the whole brain) in the <z:chebi fb="0" ids="17431">agmatine</z:chebi> treatment group compared to 15.02±4.28% of the whole brain in the experimental control group </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that <z:chebi fb="0" ids="17431">agmatine</z:chebi> treatment can reduce <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> through minimizing neuroinflammation and can lessen the danger of post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> from <z:hpo ids='HP_0000716'>depression</z:hpo> of the immune system after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>